Company: TG Therapeutics
Job title: VP, Preclinical Sciences
Emmanuel Normant is currently the vice president of preclinical sciences at TG Therapeutics, a biotech focused on heme malignancies and located in New York.
There, he oversees the early pipeline that includes a novel BTK inhibitor, an anti-PD-1 antibody and a bispecific antibody directed against CD19 and CD47. All three drugs are currently tested in phase 1 dose-escalation clinical trials in hematologic cancers.
Dr Normant joined TG Therapeutics two years ago, bringing in 20 years expertise in cancer biology, pharmacology, immuno-oncology, cancer epigenetic and preclinical sciences.
Emmanuel Normant received his pharmacy and PhD degrees from Paris-Sorbonne university.